chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Uncomfortable palpitations; Lightheadedness; This spontaneous case was reported by a consumer and describes the occurrence of PALPITATIONS (Uncomfortable palpitations) and DIZZINESS (Lightheadedness) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PALPITATIONS (Uncomfortable palpitations) and DIZZINESS (Lightheadedness). At the time of the report, PALPITATIONS (Uncomfortable palpitations) and DIZZINESS (Lightheadedness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not provided.  Treatment information was not provided.
LITTLE PINK COLOR OF THE CHEEK; This spontaneous report received from a patient concerned an 84 year old female. The patient's height, and weight were not reported. The patient's past medical history included childhood asthma, and concurrent conditions included high blood pressure, mold allergy, dust allergy, and allergy to trees. The patient experienced severe allergic reaction when treated with bnt 162 for prophylactic vaccination. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: 203A21A, expiry: 23-JUN-2021) dose was not reported, administered on 22-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On JAN-2021, Laboratory data included: COVID-19 antibody test (NR: not provided) NEGATIVE. On 22-MAY-2021, the subject experienced little pink color of the cheek. The action taken with covid-19 vaccine was not applicable. The patient recovered from little pink color of the cheek on 22-MAY-2021. This report was non-serious.
2 wk post vax pt devel temp of 104 x 2 days no other sx;
Patient & family confirmed vacciens to be administered.  All vaccine prepared and administered according to facility protocol.   Within 5 minutes following vaccines, patient developed urticaria on face and neck.  Both vaccines (HPV-9 and Flulaval) have been tolerated in previous administrations.  Patient treated with initial dosing of 25mg of benadryl PO liquid.  Upon further assessment, noted periorbital edema was witnessed and patient was administered epipen and another dose of 25mg of benadryl PO liquid.   Airway was never compromised, and patient was alert & oriented during the entire visit.  Patient was transported to local ED via EMS for further evaluation and monitoring.     Medical decision making by Dr.
Patient called the pharmacy to complain of Right arm soreness and full body aches. Patient also mentioned that his blood sugar was to high to be measured with his meter. Upon recheck it was in the 400s. He took his insulin and was instructed to seek medical attention if his blood sugar did not come down. Checking with patient the next morning he stated his blood sugar had returned to what had normally been running, but was still suffering from body aches.
Pt was given PNEUMOVAX on 10/2/12 in (Lt) deltoid. On 10/3/12 pt started to notice redness and warmth approx. 4 inches below injection site. Pt. on 10/5/12 now has large red, slightly swollen area below inj. site. Pt was told to use ice (PRN) OTC pain relievers & activity as tolerated.
Patient felt flush a few hours after administration of vaccine.  The next day patient had a headache with shooting pain upon bending.  Patient also reports body aches and some chest pressure.
Onset of dizziness approximately 5 minutes after inoculation with H1N1 and seasonal flu vaccines.  2 hours following injection, throat swelling with heavy mucous production and expectoration.  3 hours, continued throat swelling accompanied by breathing difficulties at which point in time patient sought medical assistance.  Monitored. Anti-inflammatory administered orally.  5 hours following nausea (vomiting), continued mucous production and expectoration, headache, fever, red eyes.  Following day, continued headache, mucous production, fever, dark orange urine, red eyes.  Day 3, continued headache, fever broke at 2:30PM, continued orange urine production.
cough; congestion; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (cough) and NASAL CONGESTION (congestion) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (cough) and NASAL CONGESTION (congestion). The patient was treated with BENZONATATE at an unspecified dose and frequency. At the time of the report, COUGH (cough) and NASAL CONGESTION (congestion) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) tested for COVID - Negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
pt recvd vax & 2 days earlier recvd flu vax; 9:00 evening of vax was dx w/Bell's palsy; 2 wks later pt had improved but mouth still drooped, had h/a w/dairy products, & still exp numbness;
First day: mild itching in left arm, mild pain in the throat and in the lymphs. Second day: unable to lift up left arm. Day 3-4: increased itching in left arm (very strong and expansive, under the skin, where the shot was administered).
Given a third dose of Shingrix; second dose 20210715; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 59-year-old female patient who received Herpes zoster (Shingrix) (batch number 2393s, expiry date 20th April 2023) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) (batch number 393C7, expiry date 25th October 2022) for prophylaxis.   Previously administered products included Shingrix (received 1st dose 0.5ml on 17th November 2020 at left deltoid intramuscularly, batch no:9kt7t, expiry date:13th March 2021).   On 28th December 2021, the patient received the 3rd dose of Shingrix (intramuscular) .5 ml. On 15th July 2021, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 15th July 2021, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 28th December 2021, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered and drug dose administration interval too long were unknown.  Additional details were provided as follows: The nurse from a medical office stated that a patient was accidently given a third dose of the Shingrix vaccine on the day of reporting, which led to extra dose administered. The patient was not exhibiting any side effects as of the time she called.  The patient also received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule Documenting per content and encouraged her to call back if had any further details. The reporter consented to follow up.
T\\\]his spontaneous report as received from a licensed practical nurse (also reported as registered nurse) refers to an unknown number of patients of unknown age and gender. Since 02-JAN-2015, an unknown number of doses of PNEUMOVAX 23 (dose, route, anatomical location, lot # and expiration date were not reported), which underwent supported temperature excursions, have been administered to an unknown number of patients. No adverse effect reported. This is the one of several reports from the same reporter source. Additional information has been requested.
Pt diagnosed with insulin dependant diabetes 7/13/09.  Received GARDASIL 6/6/08, 8/8/08, & 1/2/09.  Younger sister recently diagnosed with IDDM and parent questioning possible role of vaccine.  Pt also subsequently diagnosed with hypothyroidism.
Information has been received from a registered nurse (R.N.) concerning an approximately 14 year old male patient who on 10-MAR-1997 was vaccinated with the first dose of MMR II (lot # 620001/1002D). The patient presented to the office years later and became "immune compromised". The nurse didn't know the nature of the disease. At the time of reporting, the patient's outcome was unknown. Additional information has been requested.
Case number PHEH2015US015697, is an initial spontaneous report from a medical assistant received on 12 Aug 2015. This report refers to a 21 years old patient of an unknown gender. Medical history and concomitant medications were not reported. The patient received expired FLUVRIN PFS (batch number: 145701) intramuscularly on 07 Aug 2015. No adverse event was reported.
A few hours after the shot on 4/28/21 and before going to bed, I noticed my arm was stiff (normally happens with the flu shot, too). No other symptoms. When I woke up in the morning around 6AM my arm was in extreme pain. I had a pins and needles feeling starting in my elbow that went to my finger tips. The pain was so bad I couldn't move my arm much. Also after waking up, I had a headache and stomach cramps with diarrhea. I took some acetaminophen for the pain. After a few more hours, around 12PM, the headache worsened, I was weak, my neck was mildly stiff and I had a low-grade fever (around 99).   After a couple more hours, around 2PM, the arm pain worsened and extended from just below my shoulder to my fingertips. I had a previous index finger injury a year prior and it was beginning to hurt again. I was very weak at this point. I had to hold my arm perfectly still or feel intense pain.  After eating and taking additional pain relieving medicine I began to feel better around 6PM. The arm pain persisted, although lessened, through the night. When I awoke the next morning it was almost gone, but the pain in my index finger remained. 17 days later I woke with the same pain in my right index finger. I've never injured this finger or had arthritis. It persisted and was very painful for several week. Even today, 4 months later, I still have a dull pain in both index fingers that sometimes worsens randomly.
pain in tooth; pain in jaw; diarrhea; pain in the feet/hands; painful headache; muscle aches; vomiting; joint pain; fever of 102.4; This spontaneous case was reported by a consumer and describes the occurrence of TOOTHACHE (pain in tooth), PAIN IN JAW (pain in jaw), DIARRHOEA (diarrhea), PAIN IN EXTREMITY (pain in the feet/hands) and HEADACHE (painful headache) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported.  Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) for an unknown indication.   On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-May-2021, the patient experienced TOOTHACHE (pain in tooth), PAIN IN JAW (pain in jaw), DIARRHOEA (diarrhea), PAIN IN EXTREMITY (pain in the feet/hands), HEADACHE (painful headache), MYALGIA (muscle aches), VOMITING (vomiting), ARTHRALGIA (joint pain) and PYREXIA (fever of 102.4). The patient was treated with IBUPROFEN at a dose of 1 dosage form. At the time of the report, TOOTHACHE (pain in tooth), PAIN IN JAW (pain in jaw), DIARRHOEA (diarrhea), PAIN IN EXTREMITY (pain in the feet/hands), HEADACHE (painful headache), MYALGIA (muscle aches), VOMITING (vomiting), ARTHRALGIA (joint pain) and PYREXIA (fever of 102.4) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-May-2021, Body temperature: 102.4 (High) 102.4.         Non-pharmacological treatment included use of ice pack.
arm soreness; pregnancy; This spontaneous prospective pregnancy case was reported by a physician and describes the occurrence of PAIN IN EXTREMITY (arm soreness) and MATERNAL EXPOSURE DURING PREGNANCY (pregnancy) in a 32-year-old female patient (gravida 2, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No medical history information provided.  Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for Prenatal care, ALUMINIUM HYDROXIDE GEL, DRIED, MAGNESIUM CARBONATE (PEPCID [ALUMINIUM HYDROXIDE GEL, DRIED;MAGNESIUM CARBONATE]) for an unknown indication.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. The patient's last menstrual period was on 25-Aug-2020 and the estimated date of delivery was 25-May-2021. On 03-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm soreness) and MATERNAL EXPOSURE DURING PREGNANCY (pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-third week of the pregnancy. The delivery occurred on an unknown date, which was reported as Unknown. For neonate 1, The outcome was reported as Unknown. On 03-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (pregnancy) had resolved. At the time of the report, PAIN IN EXTREMITY (arm soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment information was provided.
Swollen tender lymph node in upper neck (under chin) on right side.; This is a spontaneous report from a contactable consumer (patient).   A 50-year-old female patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Right on 09Feb2021 10:30 (Lot Number: EL3247), at the age of 50-years at vaccination, as SINGLE DOSE for covid-19 immunisation.  Medical history included Hypertension, hypothyroidism, elevated platelets. The patient did not have COVID-19 prior vaccination. The patient previously took prednisone and experienced fast heart rate. Concomitant medications included varicella zoster vaccine rge (cho) (SHINGRIX) taken for an unspecified indication from 25Jan2021 to 25Jan2021; irbesartan taken for an unspecified indication, start and stop date were not reported; amlodipine besylate taken for an unspecified indication, start and stop date were not reported; levothyroxine sodium taken for an unspecified indication, start and stop date were not reported.  The patient experienced swollen tender lymph node in upper neck (under chin) on right side on 13Feb2021 14:00 with outcome of not recovered. No treatment was given for the event. The patient has not been tested for COVID-19 post vaccination.
Suddenly this morning, 13 days after receiving the first Covid Moderna vaccine - my arm is red and feverish at injection site.  In the meantime starting Sunday, Feb. 14th, I had pain in right chest and right upper back, that I contributed to making a wrong move and straining muscles.  The back pain is better, but I still have it when I reach high , move wrong, or take a deep breath.
6-17-16, Date of event at 12:10 vaccines given. 6-18-16, No symptoms or signs of anything. 6-21-16, Patient stable no symptoms or signs.
Initial report received from healthcare professional on 19 September 2014. A 62-year-old female patient, whose concomitant medications were not reported, had received a dose of FLUZONE QIV (batch number UI196AD, intramuscular in left deltoid) having expiry date 30 June 2015 on 17 September 2014. The patient has no illness at the time of vaccination and is allergic to sulfa drugs, statin drugs and latex. It was reported that on 17 September 2014, on the same day after receiving FLUZONE QIV vaccine, the patient experienced left arm pain and nausea. The patient's corrective treatments and laboratory investigations were not reported. At the time of this report, the outcome was unknown. Documents held by sender: none. Follow-up information received from a healthcare professional on 23 December 2014. The patient had received 0.5 ml dose of FLUZONE QIV.
Nausea, fatigue, and I fainted the evening of 4/28/21.
patient had both shots done on Friday 9/27/2019 at pharmacy. Patient came in with a swollen and itchy arm.
Local tenderness and localized swelling at time of injection. The injection site swelling gone in 12 hours. The localized pain remained and became worse. 16 days later, minimal pain (all the time), which increases substantially with movement. The pain moved up my arm into shoulder and neck. Reported to doctor on 2/23/2022 and to pharmacist on 2/26/2022. Doctor suggested heat. Pharmacist suggested ibuprofen. Neither seems to relieve the pain. I allow the pain to limit my activities. If the pain increases with a certain movement or activity, I stop what I'm doing.
Tired; Sore; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non-HCP), Program ID: The reporter is the patient.  An elderly male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: FATIGUE (non-serious), outcome "unknown", described as "Tired"; PAIN (non-serious), outcome "unknown", described as "Sore".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pressure and ground glass sensation in sternal area when breathing; pressure and ground glass sensation in sternal area when breathing; Joint pain in all major joints inc. metacarpal/metatarsal/phylangeal and interphylangeal joints; extreme fatigue; This is a spontaneous report from a non-contactable physician (Patient). A 42-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 26Jan2021 10:00 (Batch/Lot number was not reported) (at the age of 42 years) as dose 1, single for covid-19 immunisation. Medical history included drug hypersensitivity (sulfa) from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. Patient had no COVID prior vaccination. The patient experienced pressure and ground glass sensation in sternal area when breathing, joint pain in all major joints inc. metacarpal/metatarsal/phylangeal and interphylangeal joints, extreme fatigue, all on 26Jan2021 with outcome of recovering with no treatment. Events resulted in: Doctor or other healthcare professional office/clinic visit. The patient underwent lab tests and procedures which included covid-19: negative on 05Feb2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information was expected.
The morning after the vaccination I was extremely dizzy from the time I got up at 7 Am until about 12 Pm. After Noon, I did not have any other adverse reactions.
had trouble breathing; toung was greatly swolen; This is a spontaneous report from a contactable consumer (patient) reported that an 83-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3246, expiration date: not reported), via an unspecified route of administration in the left arm on 11Jan2021 09:30 at a single dose for COVID-19 immunization. Medical history included very mild chronic obstructive pulmonary disease (COPD) from an unknown date. Concomitant medications included sertraline, temazepam, levothyroxine and pravastatin. It was reported that on 11Jan2021, the patient had injection at 9:30 am then at 6 pm, had trouble breathing and tongue was greatly swollen (reported as "toung was greatly swolen"). The patient called ambulance and went to emergency room/department or urgent care. As treatment, the patient received saline IV, banophen and prednisone. The outcome of the events was not recovered.
The first day, he did not feel real good, felt weak. On Saturday had fever, no appetite. Sat down and couldn't get up, joint pain had no balance.  The fever kept going and down. Felt weak, didn't feel like moving and slept most of the time.  Felt better on Sunday, a little weak.
Myalgia, SkinRash, CoughWheeze, Rash, UrticariaPruritus, NauseaVomiting, chest pressure, cough, chills, body aches, nausea (no vomiting), R arm rash approx 3 inches in diameter Narrative: Most symptoms (chills, aches, nausea) subsided within 48 hours but right arm rash and cough were worse at 48 hours; Antibiotics prescribed
Tender, red quarter/silver dollar sized raised area at sight of injection.  Not hot and not bothering the patient.
VACCINATION WAS RECEVIED THE MORNING OF 1/5/2021- IN THE EVENING OF THAT DAY RESIDENT SUSTAINED A FALL AND WAS TRASNPORTED TO FACILITY FOR TREATMENT. IT IS NOT UNUSUAL THAT RESIDENT WAS SELF TRANSFERRING AND HAS A HISTORY OF FALLS.
This spontaneous case was reported by a patient and describes the occurrence of IMMUNISATION REACTION (had a reaction to dose 3) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (had a reaction to dose 3). At the time of the report, IMMUNISATION REACTION (had a reaction to dose 3) outcome was unknown.            Concomitant drugs were not reported. It was reported that patient had 4 doses of Moderna and patient was a senior. Treatment medications were not provided.      Reporter did not allow further contact
she put in and I had pain in my arm; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for Injection, Batch/Lot number: EL1283) via an unspecified route of administration on 21Jan2021 as single dose for covid-19 immunisation. The patient's medical history included weight abnormal, diabetes mellitus, fibromyalgia and autoimmune disorder. The patient's concomitant medications were not reported. The reporter states she put in and patient had pain in arm on an unspecified date. The outcome of the event was unknown.  No further information was reported.
Mom reports head to toe rash, fevers of 100-102 degrees, fussy/irritable child over past 3 days (today 11/27/17).
Extreme fatigue; Malaise; chills; Injection site pain and tenderness; muscular pain; This is a spontaneous report from a non-contactable physician (reporting for herself).  A non-pregnant 34-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration in the left arm on 13Jan2021 6:00 PM at a single dose for COVID-19 immunization.  Medical history included: COVID-19 (prior to the vaccine).  The patient's concomitant medications were not reported. The patient had no known allergies.  The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), on 24Dec2020 3:00 PM in the left arm, at 34 years old for COVID-19 immunization.  The patient experienced extreme fatigue, malaise, chills, injection site pain and tenderness and muscular pain on 14Jan2021.  Therapeutic measures were taken as a result of the events which included ibprophen (ADVIL).  The outcome o the events was recovered in Jan2021.    No follow-up attempts are possible; information about batch/lot number cannot be obtained.